P.01

# CLARK & BRODY

1090 Vermont Avenue, NW, Suite 250 Washington, D.C. 20005 Telephone: (202) 835-1111

CENTRAL FAX CENTER OCT 1 4 2008

RECEIVED

Facsimile: (202) 835-1755

## FACSIMILE TRANSMITTAL SHEET

PLEASE DELIVER TO: EX. MOHAMMAD Y. MEAH, GROUP ART UNIT 1652

U.S. PATENT AND TRADEMARK OFFICE

FACSIMILE NUMBER:

571-273-8300

SENDER:

Christopher W. Brody

DATE:

October 14, 2008

U.S. SERIAL NO.

10/031,938

DOCKET NO.

71247-0085

NUMBER OF PAGES:

(INCLUDING COVER PAGE)

# CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the attached Amendment under 37 CFR 1.312 for U.S. Serial No. 10/031,938 is being transmitted to the U.S. Patent and Trademark Office on the date shown above.

Respectfully submitted.

If all pages are not received, please contact Melissa Garton at (202) 835-1111.

This message is intended solely to be used by the individual or entity to which it is addressed. It may contain information which is privileged, confidential and otherwise exempt by law from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to its intended recipient, you are herewith notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us by telephone immediately and return this communication to us at the above address via the United States Postal Service. Thank you.

#### **ATTN: MAIL STOP ISSUE FEE**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

OCT 1 4 2008

In re the Application of:

Srinivas KAVERI et al.

Examiner:

Mohammad Y. Meah

Application No.: 10/031,938

Art Unit:

1652

Filed: July 22, 2002

Attorney Docket No.: 71247-0085

For: CATALYTIC ANTI-FACTOR VIII ALLO-ANTIBODIES

### **AMENDMENT UNDER RULE 1.312**

### MAIL STOP ISSUE FEE Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice of Allowance dated, October 1, 2008, please amend the application as set forth below.

Amendments to the claims are submitted on page 2.

Remarks are submitted on page 6.